Clinical Trial: A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07509892) titled 'A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus' on March 28.

Brief Summary: To assess the efficacy and safety of TQH3906 in treating systemic lupus erythematosus.

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: Systemic Lupus Erythematosus

Intervention: DRUG: TQH3906 capsule

The TQH3906 capsule is a Tyrosine Kinase 2 (TYK2) inhibitor.

DRUG: TQH3906 placebo

Placebo without drug.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Published by HT Digital Content Services with permission from Health Dail...